Related Experiment Video
Updated: Sep 19, 2025
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
39.1K
[Vaccination recommendations for psoriasis patients treated with biologics]
Thomas Damsin1, Gilles Absil1, Florence Libon1
1Service de Dermatologie et de Vénéréologie, CHU Liège, Belgique.
Revue Medicale De Liege
|June 16, 2025
Summary
Psoriasis patients on IL17/IL23 biologics generally follow standard vaccination guidelines. While biologics can cause mild immunosuppression, current evidence suggests no increased risk for infections covered by conventional vaccines.
Area of Science:
- Immunology
- Dermatology
- Pharmacology
Context:
- Moderate to severe psoriasis treatments commonly involve interleukin-17 (IL17) and interleukin-23 (IL23) antagonists.
- These biologic therapies offer high efficacy and a favorable long-term safety profile.
- A potential side effect of these targeted treatments is mild immunosuppression.
Purpose:
- To provide guidance on vaccination recommendations for patients undergoing biological therapy for psoriasis.
- To assess the specific risks associated with IL17 and IL23 antagonists concerning infectious diseases and vaccine efficacy.
Summary:
- Biologic treatments for psoriasis, such as IL17 and IL23 antagonists, can lead to mild immunosuppression, increasing susceptibility to infections.
- Patients on these biologics require counseling regarding vaccinations before and during treatment.
- Live attenuated vaccines generally necessitate treatment interruption, while inactivated vaccines may be continued.
- Current data indicate no elevated risk for infections covered by standard vaccines in patients treated with IL17 or IL23 antagonists.
Impact:
- Ensures appropriate vaccination strategies for psoriasis patients on biologics, optimizing safety and treatment outcomes.
- Highlights the need for continued adherence to general population vaccination guidelines for these patients.
- Contributes to informed clinical decision-making regarding the management of psoriasis and infectious disease prevention.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
240
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
240
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
01:30Cancer Vaccines
522
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
522
01:29Inflammatory Bowel Disease IV: Pharmacological Management
205
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
205
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
212
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
212
01:24T Cell Types and Functions
1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K